TrialClinical pharmacokinetics2026
Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.
Neha Thakre et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.